Saskatchewan
Ministry of
Health

Drug Plan and Extended Benefits Branch

November 1, 2012
Bulletin #138
ISSN 1923-0761

SASKATCHEWAN FORMULARY BULLETIN

Update to the 62nd Edition of the Saskatchewan Formulary

Revised Exception Drug Status (EDS) Criteria Effective November 1, 2012:

- **ticagrelor, tablet, 90mg (Brilinta-AST)**

Inclusion:

To be taken in combination with ASA 75mg to 150mg daily[a] for patients with acute coronary syndrome (i.e., ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], or unstable angina [UA]) with ONE of the following:

1. Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis,[b] **or** recurrent STEMI, **or** NSTEMI **or** UA after prior revascularization via percutaneous coronary intervention (PCI).

OR

2. STEMI and undergoing revascularization via PCI.

OR

3. NSTEMI or UA and high risk angiographic anatomy[c] and undergoing revascularization via PCI.

Notes:

(a) Co-administration of ticagrelor with high maintenance dose ASA (>150mg daily) is not recommended.

(b) Definite stent thrombosis, according to the American Research Consortium, is a total occlusion originating in or within 5mm of the stent, **or** is a visible thrombus within the stent, **or** is within 5mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis.

(c) High risk angiographic anatomy is defined as any of the following: left main stenting, high risk bifurcation stenting (i.e., two-stent techniques), long stents ≥ 38mm or overlapping stents, small stents ≤ 2.5mm in patients with diabetes.

(d) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment.

Requests for patients with a clearly demonstrated allergy or intolerance to ASA may be considered. (Allergy will be as manifested by asthma or nasal polyps. Intolerance will be as manifested by gastrointestinal hemorrhage.)

Requests meeting the above inclusion criteria will be eligible for an approval period of 12 months.

Saskatchewan Ministry of Health
Drug Plan and Extended Benefits Branch
2nd Floor, 3475 Albert Street
Regina, Saskatchewan S4S 6X6
(306) 787-3317
1-800-667-7581

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.